Navigation Links
The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research
Date:7/6/2009

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely available to researchers to test potential new treatments for the disease.

WM occurs as low-grade B-cell non-Hodgkin lymphoma, characterized by B-lymphocytes in the bone marrow, and an abnormal level of the protein monoclonal immunoglobulin M (IgM). Though the disease is slow-growing, a curative treatment has yet to be developed. Cell lines are invaluable in understanding the genetics and biology of cancerous cells. The development of a biologically stable and satisfactorily representative WM cell line will enable researchers throughout the world to test their latest ideas on bio-identical cells and thus compare their results with those of other researchers.

Researchers agree that new cell lines are urgently needed as it is widely understood that the three most used existing WM cell lines may not accurately represent the disease.

"Numerous scientists studying WM report that one of the barriers to finding a cure is the lack of a standardized WM cell line," said LLS Chief Scientific Officer Louis J. DeGennaro, Ph.D. "Together, LLS and IWMF are committed to seeing this critical asset developed in a way so as not to fundamentally change the cellular and functional characteristics of the original tumor, and thus enable researchers to better understand the unique aspects of WM biology and advance more effective treatments for WM patients."

Under the agreement, LLS and IWMF will seek applications and select up to three laboratories to co-fund for up to $100,000 for one year. Continued funding, potentially for up to two additional years, will be contingent on available funds and assessments of progress t
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
2. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
3. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
4. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
5. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
6. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
7. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. Not the protein, but its location in the cell, determines the onset of leukemia
10. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
11. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... Wright, Co-Chair of the Alliance for Biosecurity and ... before the House Labor, Health and Human Services, ... of developing drugs, vaccines and other medical countermeasures ... catastrophic health emergencies. Effective medical countermeasures for many ...
... to Better Serve Asia-Pacific Clinical Trial Enrollment ConcernsNEWTON, ... leader in patient recruitment for clinical trials, has ... G.K., in Osaka, Japan. The company will be ... device companies, as well as CROs and SMOs, ...
... Sopherion Therapeutics, LLC, a biopharmaceutical company focused ... announced that it completed enrollment in its pivotal ... in metastatic HER-2-overexpressing breast cancer. This is ... product in combination with the current standard of ...
Cached Biology Technology:Alliance for Biosecurity Testifies Before Congress on Funding for Medical Countermeasure Development 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 2Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace 3Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 2Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer 3
(Date:7/13/2015)... 13, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced sampling of ClearPad ® ... integration (TDDI) product targeting smartphones and tablets. This ... Synaptics , best-in-class touch controller IP and ... developed in the company,s Japan Design Center. TDDI ...
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... greenhouse-gas emissions in comparison to fossil fuels. In the ... highlight a new study that factors in environmental costs ... short. The authors urge governments to be far more ... are more environmentally friendly than fossil fuels., Because fossil ...
... - The crystal structure of a molecule from a primitive ... more about the evolution of life from the simple to ... fungus protein bound to an RNA molecule, scientists from Purdue ... able to visualize how life progressed from an early self-replicating ...
... - Investigators at the University of Alabama at,Birmingham ... a,chemical ,messenger, leading to autoimmune disorders like rheumatoid,arthritis ... occurring chemical interleukin 17,(IL-17), an immunity protein. ... in autoimmune and,inflammatory responses, aside from its commonly ...
Cached Biology News:Scientists find missing evolutionary link using tiny fungus crystal 2Protein's new role discovered in autoimmune disease 2
... Gel/Mount is an aqueous-based mounting medium ... tissue sections. Gel/Mount is especially recommended ... allophycocyanin or FluoroBlue. It can also ... such as fluorescein (FITC), Rhodamine (TMRITC) ...
...
... Rabbit polyclonal to JNK1 (phospho T183 + ... an internal domain containing phosphorylated T183/Y185. Reactivity ... Rat. Not yet tested in other species. ... subgroups, including the ERK, JNK, and p38 kinases. ...
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
Biology Products: